Dr. Volker M. Lauschke, Karolinska Institutet
Topic: Chemogenomic screening in organotypic and microphysiological patient-derived 3D cultures - towards reliable drug target identification in metabolic diseases
Volker M. Lauschke (V.M.L.) is Professor and group leader in Translational Pharmacology at Karolinska Institutet (KI), Stockholm, Sweden and Deputy Director of the Institute of Clinical Pharmacology (IKP) in Stuttgart, Germany. His research group engineers organotypic and microphysiological human tissue models to develop novel therapeutic strategies for inflammatory conditions (NASH), infectious diseases (COVID-19 and hemorrhagic fevers) and complex metabolic diseases (type 2 diabetes).
V.M.L. has authored over 140 papers in peer-reviewed journals and is the recipient of multiple awards in the area of genetics, pharmacology and drug discovery, including the Lennart Philipson Prize 2017, the AAPS High Impact Award 2020 and the ISSX Karl Netter Award 2023. Furthermore, he is a Clarivate Highly Cited Researcher 2022 in Pharmacology (1 of 3 in Sweden). Besides his academic work, he is co-founder and CEO of HepaPredict AB, a biotech company offering 3D human liver models for drug discovery and development, as well as co-founder and CSO of PersoMedix AB, offering services for personalized drug response predictions.